Virus derived antimicrobial peptides

Details Virus derived antimicrobial peptides Virus derived antimicrobial peptides

2008-07-11

2011-12-06

Russel, Jeffrey E (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S003300, C514S003400, C514S003700, C514S003800, C514S021400, C514S021500, C530S325000, C530S326000, C530S327000

Reexamination Certificate

active

08071540

ABSTRACT:
Described herein are peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides, designated LBU, WLBU and WR, are analogs of the Lentivirus Lytic Peptide 1 (LLP1) amino acid sequence. The antimicrobial peptides are monomers or multimers of peptides referred to as the Lytic Base Unit (LBU) peptides, derived from the LLP1 analogs and also having antimicrobial activity. Also described herein are using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. Methods of killing fungi, such asCandidaandCryptococcusspecies, and bacteria, such asB. anthracis, are provided herein. Methods of neutralizing enveloped viruses, such as poxvirus, herpesvirus, rhabdovirus, hepadnavirus, baculovirus, orthomyxovirus, paramyxovirus, retrovirus, togavirus, bunyavirus and flavivirus, including influenza virus and HIV-1 also are provided herein. Solid phase substrates and peptide-cargo complexes comprising the peptides also are provided.

REFERENCES:
patent: 5504190 (1996-04-01), Houghten et al.
patent: 5714577 (1998-02-01), Montelaro et al.
patent: 5945507 (1999-08-01), Montelaro et al.
patent: 5981698 (1999-11-01), Brittain
patent: 6835713 (2004-12-01), Mietzner et al.
patent: 6887847 (2005-05-01), Montelaro et al.
patent: 2003/0036627 (2003-02-01), Montelaro et al.
patent: 2004/0043041 (2004-03-01), Baker et al.
patent: 2005/0025761 (2005-02-01), Thorpe et al.
patent: 2005/0282239 (2005-12-01), Allbritton et al.
patent: 2007/0225213 (2007-09-01), Kosak
patent: 2009/0053278 (2009-02-01), Fatora et al.
patent: 0273716 (1993-08-01), None
patent: WO 03103718 (2003-12-01), None
patent: WO 2008070083 (2008-06-01), None
Arroyo et al., “Membrane Permeabilization by Different Regions of the Human Immunodeficiency Virus Type 1 Transmembrane Glycoprotein gp41”, J. Virol. 69: 4095-4102, 1995.
Beary et al., “Interruption of T-Cell signal transduction by lentivirus lytic peptides from HIV-1 transmembrane protein”, Journal of Peptide Research, 51: 75-79, 1998.
Blondelie et al., “Design of Model Amphipathic Peptides Having Potent Anitmicrobial Activities”, Biochemistry, 31:12688-12694, 1992.
Burton, E. et al. Antibiofilm activity of GlmU enzyme inhibitors against catheter-associated uropathogens. Antimicrob Agents Chemother 50, 1835-1840 (2006).
Caron, N. J., Torrente, Y., Camirand, G., Bujold, M., Chapdelaine, P., Leriche, K., Bresolin, N., and Tremblay, J. P. Intracellular delivery of a Tat-eGFP fusion protein into muscle cells, Mol Ther. 3: 310-8, 2001.
Chernomordik, A. et al., An Amphipathic Peptide from the C-Terminal Region of the HIV Envelope Glycoprotein Causes Pore Formation in Membranes, J. Virol. 68, 7115-7123 (1994).
Chou et al., “Prediction of the Secondary Structure of Proteins From Their Amino Acid Sequence”, Adv Enz Relat Areas Mol Bio, 47: 45-146, 1978.
Chou et al., Prediction of Protein Conformation, Biochemistry 13:222, 1974.
Cirioni, O. et al. Pre-treatment of central venous catheters with the cathelicidin BMAP-28 enhances the efficacy of antistaphylococcal agents in the treatment of experimental catheter-related infection. Peptides 27, 2104-2110 (2006).
Comardelle et al., “A Synthetic Peptide Corresponding to the Carboxy Terminus of Human Immunodeficiency Virus Type 1 Transmembrane Glycoprotein Induces Alterations in the Ionic Permeability ofXenopus laevisOocytes”, AIDS Research & Human Retroviruses, 13: No. 17, pp. 1525-1532, 1997.
Deslouches et al., Activity of the de novo engineered antimicrobial peptide WLBU-2 againstP. aeruginosain human serum and whole blood: implications for systemic applications, Antimicrob Agents Chemother Aug. 2005;49(8):3208-16.
Deslouches, B. et al. De novo generation of cationic antimicrobial peptides: influence of length and tryptophan substitution on antimicrobial activity. Antimicrob Agents Chemother 49, 316-322 (2005).
Deslouches, B. et al. De novo-derived cationic antimicrobial peptide activity in a murine model ofP. aeruginosabacteraemia. J Antimicrob Chemother 60, 669-672 (2007).
Dietz, G. P. and Bahr, M. Delivery of bioactive molecules into the cell: the Trojan horse approach, Mol Cell Neurosci. 27: 85-131, 2004.
Eisenberg and Wesson, “The Most Highly Amphiphilic .A-inverted.-Helics Include Two Amino Acid Segments in Human Immunodeficiency Virus Glycoprotein 41”, Biopolymers, 29: 171-177, 1990.
Eisenberg et al., “The hydrophobic moment detects periodicity in protein hydrophocity”, Proc. Natl. Acad. Sci. U.S.A., 81:140-144, 1984.
Eisenberg et al., “Analysis of Membrane and Surface Protein Sequences with the Hydrophobic Moment Plot,” J. Mol. Biol. 179:125, 1984.
El-Ghannam, A, K Ahmed, and M Omran, Nanoporous Delivery System to Treat Osteomyelitis and Regenerate Bone: Gentamicin Release Kinetics and Bactericidal Effect, J Biomed Mater Res B Appl Biomater May 2005;73(2):277-84).
Ellman, G. L., “Tissue Sulfhydryl Groups,” Arch. Biochem. 82: 70-77, 1959.
Falagas, M.E., Fragoulis, K., Bliziotis, I.A. & Chatzinikolaou, I. Rifampicin-impregnated central venous catheters: a meta-analysis of randomized controlled trials. J Antimicrob Chemother 59, 359-369 (2007).
File,TM. “Overview of Resistance in the 1990s”, Chest. 115:3S-8S. Mar. 1999 Supplement.
Fontenot et al., “A Survey of Potential Problems and Quality Control in Peptide Synthesis by the Fluorenylmethoxycarbonyl Procedure”, Peptide Research, 4:19-25, 1991.
Friedrich et al., “Salt-Resistance Alpha-Helical Cationic Antimicrobial Peptides”, Antimicrobial Agents and Chemotherapy, 43: 1542-1548, 1999.
Fujii et al., A molecular model for membrane fusion based on solution studies of an amphiphilic peptide from HIV gp41 Protein Sci. 1:1454, 1992.
Ganz and Lehrer, “Antimicrobial peptides of leukocytes”, Current Opinion in Hematology, 4: 53-58, 1997.
Gamier et al., “Analysis of the Accuracy and Implications of Simple Methods for Predicting the Secondary Structure of Globular Proteins”, J. Mol. Biol., 120: 97-120, 1978.
Gawrisch et al., Interaction of Peptide Fragment 828-848 of the Envlope Glycoprotein of HIV with Lipid Bilayers, Biochemistry 32, 3112-3118 (1993).
Guelen, L., Paterson, H., Gaken, J., Meyers, M., Farzaneh, F., and Tavassoli, M. TAT-apoptin is efficiently delivered and induces apoptosis in cancer cells, Oncogene. 23: 1153-65, 2004.
Habermann et al., Bee and wasp venoms, Science 177:314, 1972.
Hancock. R.E., “Host Defence (Cationic) Peptides: What Is Their Future Clinical Potential?”, Drugs, 57: 469-473, Adis International Limited, 1999.
Ho et al., (2001) Cancer Research 61:474-477; Mai, et al. (2002), Efficiency of Protein Transduction is Cell Type-dependent and is enhanced by Dextran Sulfate, J. Biol. Chem. 277(33):30208-218.
Honig, B. (1999) Protein folding: from the levinthal paradox to structure prediction. J. Mol. Biol. vol. 293, pp. 283-293. Review.
Hwang and Vogel, “Structure-function relationships of antimicrobial peptides”, Biochem. Cell Biol., 76: 235-246, 1998.
Isaacs, C.E. et al. Inactivation of herpes simplex virus clinical isolates by using a combination microbicide. Antimicrob Agents Chemother 50, 1063-1066 (2006).
Kalia, V. et et al (2003) Rational site-directed mutations of the LLP1 and LLP-2 lentivirus lytic peptide domains in the intracytoplasmic tail of human immunodeficiency virus type 1 gp41 . , J. Virol. vol. 77, pp. 3634-3646.
Koenig, B. et al., Effect of the conformation of a peptide from gp41 on binding and domain formation in model membranes, Mol. Membrane Biol. 12, 77-82 (1995).
Lehrer, R. I., M. E. Selsted, D. Szklarek, and F. J. 1983. Antibacterial Activity of Microbicidal Cationic Proteins 1 and 2, Natural Peptide Antibiotics of Rabbit Lung Macrophages Infect. Immun. 42: 10-4, 1983.
Mai, et al. (2002) “Efficiency of Protein Transduction Is Cell Type-dependent and Is Enhanced by Dextran Sulfate,” J. . Biol. Chem. 277(33):30208-218.
Merrifield et al., &#

Affiliated with

Also associated with

Rating

Virus derived antimicrobial peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Virus derived antimicrobial peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Virus derived antimicrobial peptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4309347